Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 28, 2016; 22(36): 8203-8210
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8203
Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8203
Table 1 Clinicopathological findings for patients with gastric cancer with enteroblastic differentiation
Case | 1 | 2 | 3 | 4 | 5 | 6 |
Age, yr | 61 | 77 | 78 | 75 | 80 | 83 |
Male/female | Male | Male | Male | Male | Female | Male |
Tumor location: U/M/L | L | M | U | U | L | M |
Tumor size, mm | 8 | 11 | 14 | 18 | 6 | 36 |
Macroscopic type | 0-IIc | 0-IIc | 0-IIc | 0-IIa | 0-IIc | 0-IIa + I |
H. pylori infection | HPIgG+ | HPIgG+ | HPIgG- | NA | HPIgG+ | HPIgG+ |
Procedure method | ESD | ESD | ESD with additional surgery | ESD | ESD | ESD with additional surgery |
Depth of invasion (μm) | M | SM (1500) | SM (1000) | SM (200) | M | SM (2000) |
Lymphatic invasion | (-) | (-) | (-) | (-) | (+) | (+) |
Venous invasion | (-) | (+) | (+) | (+) | (-) | (+) |
Observation period (mo) | 51, ANED | 42, ANED | N/A | 38, ANED | N/A | 28, ANED |
Immunohistochemical analysis | ||||||
AFP | (+) | (-) | (-) | (-) | (-) | (-) |
Glypican3 | (+) | (+) | (+) | (+) | (-) | (+) |
SALL4 | (+) | (-) | (-) | (-) | (+) | (-) |
MUC2 | (-) | (-) | (-) | (+) | (-) | (-) |
MUC5AC | (-) | (-) | (-) | (+) | (-) | (-) |
MUC6 | (-) | (+) | (+) | (+) | (-) | (+) |
CD10 | (+) | (+) | (+) | (+) | (+) | (+) |
P53 | (-) | (-) | (+) | (+) | (+) | (-) |
Table 2 Results of comparison between patients with gastric cancer with enteroblastic differentiation and conventional gastric cancer n (%)
GCED | CGC | P value | |
Number of lesions, n | 6 (2.7) | 209 (97.3) | N/A |
Age, yr; median (range) | 75.7 (61-83) | 72.7 (40-92) | 0.39 |
Male/female | 5/1 | 139/47 | 0.63 |
Tumor location: U/M/L | 2/2/2 | 23/91/95 | 0.24 |
Tumor size, mm, mean (range) | 15.0 (6-36) | 15.2 (2-60) | 0.96 |
Macroscopic type: elevated type/flat or depressed type | 2/4 | 92/117 | 0.60 |
Ulceration | 0 | 19 (9.0) | 0.43 |
Depth of invasion: M/SM | 2/4 | 185/24 | < 0.01 |
Rate of submucosal invasive cancer | 66.60% | 11.40% | |
Median SM invasive depth, μm (range) | 1500(200-2000) | 795.8(100-5000) | 0.40 |
Lymphatic invasion | 2 (33.3) | 5 (2.3) | < 0.01 |
Venous invasion | 4 (66.6) | 1 (0.4) | < 0.01 |
Positive horizontal margin | 0 | 9 (4.3) | 0.60 |
Positive vertical margin | 1 (16.7) | 5 (2.3) | < 0.05 |
Curative resection1 | 1 (16.7) | 186 (89.0) | < 0.01 |
The following is a comparison only for SM invasive cancer | |||
Number of SM invasive lesions, n | 4 | 24 | N/A |
Lymphatic invasion | 1 (25) | 5 (20.8) | 0.88 |
Venous invasion | 4 (100) | 1 (4.2) | < 0.01 |
Positive horizontal margin | 0 | 1 (4.2) | 0.33 |
Positive vertical margin | 1 (16.7) | 2 (8.3) | 0.55 |
Curative resection1 | 0 | 12 (50) | < 0.01 |
- Citation: Matsumoto K, Ueyama H, Matsumoto K, Akazawa Y, Komori H, Takeda T, Murakami T, Asaoka D, Hojo M, Tomita N, Nagahara A, Kajiyama Y, Yao T, Watanabe S. Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation. World J Gastroenterol 2016; 22(36): 8203-8210
- URL: https://www.wjgnet.com/1007-9327/full/v22/i36/8203.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i36.8203